Cerus Corporation Financial Results Announcement for Q4 2024
Cerus Corporation (Nasdaq: CERS) is set to release its anticipated fourth quarter and full-year financial results for 2024. The announcement is scheduled for a Thursday afternoon session where the company will share insights into its financial performance as well as its future expectations. This event represents a key moment for investors and stakeholders keen to understand the company's trajectory.
Details of the Upcoming Release
The financial results will be available after the market closes, providing ample time for the public to digest the information. Following the release, Cerus plans to host an engaging conference call and webcast at 4:30 P.M. ET. During this session, key executives will offer a comprehensive discussion of the results along with an overview of business operations and anticipated future developments.
How to Access the Conference Call
Participants interested in attending the webcast will be able to access the presentation slides through Cerus Corporation's Investor Relations platform. Those wishing to join the call are advised to log in around 10 minutes prior to the start time, ensuring a smooth experience.
Replay Availability
If you cannot attend the live event, don’t worry! A replay of the entire conference call will be made available on the Cerus website. It will be accessible approximately three hours post-event and will remain available until early March, allowing ample opportunity for review.
About Cerus Corporation
Cerus Corporation is on a mission that extends far beyond merely financial goals; it is committed to protecting the world's blood supply. Headquartered in Concord, Cerus is driven to become the premier global company for blood products. The organization has developed significant technologies aimed at ensuring the safety of blood components for blood centers, hospitals, and patients who rely on safe blood transfusions.
Innovative Blood Safety Solutions
One of the notable achievements of Cerus is the INTERCEPT Blood System, which provides pathogen-reduced blood products, specifically for platelets and plasma. This system is recognized globally and holds both CE mark and FDA approval, thus, representing a significant advancement in blood safety practices. Furthermore, the INTERCEPT Blood System for Cryoprecipitation has received approval in the U.S. for the safe production of a therapeutic product that combats bleeding, pivotal in emergency and surgical circumstances.
The Future of Red Blood Cell Systems
Cerus is also progressing with its INTERCEPT red blood cell system, which is currently in late-stage clinical development. This product aims to continue enhancing safety protocols for blood transfusions, potentially saving lives and improving patient outcomes across various medical scenarios.
Connect with Cerus
To learn more about their innovative approaches and products, visit the Cerus Corporation website. By following their journey, stakeholders can stay updated on advancements and contributions to the healthcare landscape. Cerus is poised to redefine the future of blood safety, ensuring that patients receive the highest standard of care.
Frequently Asked Questions
What financial results will Cerus announce?
Cerus will announce its fourth quarter and full-year financial results for 2024, detailing their performance and outlook.
When is the conference call scheduled?
The conference call is scheduled for 4:30 P.M. ET on the same day as the results release, following the market close.
How can I access the live webcast?
You can access the live webcast by visiting the Investor Relations page of the Cerus website before the call begins.
Will there be a replay available?
Yes, a replay will be available approximately three hours after the call and will remain accessible until early March.
What is Cerus Corporation’s primary mission?
Cerus Corporation is dedicated to safeguarding the world’s blood supply through innovative technologies and pathogen-reduced blood products.
